Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: Comparisons with liraglutide, insulin glargine, and placebo in two randomized studies

Health and Quality of Life Outcomes

Volumn 15, Issue 1, 2017, Pages

  Suzuki, Shuichi ^a   Oura, Tomonori ^a   Takeuchi, Masakazu ^a   Boye, Kristina S ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Dulaglutide; Glucagon like peptide 1; Patient reported outcomes; Type 2 diabetes

Indexed keywords

BIGUANIDE DERIVATIVE; DULAGLUTIDE; INSULIN GLARGINE; LIRAGLUTIDE; PLACEBO; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COMBINATION DRUG THERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSESSMENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; EMOTION; FEMALE; HEALTH IMPACT ASSESSMENT; HUMAN; HYPOGLYCEMIA; INJECTABLE DIABETES MEDICATION QUESTIONNAIRE JAPANESE VERSION; JAPANESE (PEOPLE); LIFESTYLE; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PERCEPTIONS ABOUT MEDICATIONS DIABETES 21 QUESTIONNAIRE JAPANESE VERSION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; QUALITY OF LIFE;

AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN GLARGINE; LIRAGLUTIDE; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; RECOMBINANT FUSION PROTEINS;

EID: 85020393265     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-017-0696-7     Document Type: Article

References (25)

1. International Diabetes Federation. IDF diabetes atlas. 7th ed. Brussels: International Diabetes Federation; 2015. http://www.diabetesatlas.org/component/attachments/?task=download&id=116. Accessed 18 May 2017.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care. 2015;38:140-9.
3. Japan Diabetes Society (Ed.). Treatment guide for diabetes 2014-2015. http://www.fa.kyorin.co.jp/jds/uploads/Treatment_Guide_for_Diabetes_2014-2015.pdf. Accessed 18 May 2017.
4. Bradley C, Gamsu DS. Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes. Diabet Med. 1994;11:510-6.
5. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673-9.
6. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543-5.
7. Ishii H, Iwamoto Y, Tajima N. An exploration of barriers to insulin initiation for physicians in Japan: findings from the Diabetes Attitudes, Wishes and Needs (DAWN) JAPAN study. PLoS One. 2012;7:e36361.
8. Ng CJ, Lai PS, Lee YK, Azmi SA, Teo CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: a systematic review. Int J Clin Pract. 2015;69:1050-70.
9. U.S Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 18 May 2017.
10. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39-48.
11. Trulicity. Prescribing information. Indianapolis: Lilly USA, LLC; 2017. http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed 18 May 2017.
12. Trulicity. Summary of product characteristics. Houten: Eli Lilly and Company; 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdf. Accessed 18 May 2017.
13. Trulicity Ateos. [Japan package insert] (in Japanese). Hyogo, Eli Lilly Japan KK; 2016. http://www.info.pmda.go.jp/downfiles/ph/PDF/530471_2499416G1029_1_07.pdf. Accessed 18 May 2017.
14. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17:974-83.
15. Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17:994-1002.
16. Yu M, Van Brunt K, Varnado OJ, Boye KS. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Diabetes Obes Metab. 2016;18:419-24.
17. Hayes RP, Meldahl ML. Perceptions about medications-diabetes: further revision and validation. International Society for Quality of life research; 2009. p. A-83. Abstract 104/1252
18. Ishii H, Tsujii S, Tanaka M, Furuya M, Iburi T, Ueda R, et al. Development of insulin Delivery System questionnaire in Japanese (IDSQ-J) and reproducibility and adequacy assessment (in Japanese). J Japan Diab Soc. 2009;52:209-21.
19. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
20. Ikeda S, Shiroiwa T, Igarashi I, Noto S, Fukuda T, Saito S, et al. Developing a Japanese version of the EQ-5D-5L value set (in Japanese; abstract in English). J Natl Inst Public Health. 2015;64:47-55.
21. Ishii H. Treatment satisfaction among patients with weekly exenatide, measurement with DTSQ (in Japanese). Jpn J Med Pharm Sci. 2014;71:135-43.
22. Boye KS, Matza LS, Walter KN, Van Brunt K, Palsgrove AC, Tynan A. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12:219-30.
23. Ishii H, Anderson JH Jr, Yamamura A, Takeuchi M, Ikeda I. Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract. 2008;81:169-78.
24. Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H, et al. Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health. 2006;9:47-53.
25. Reaney M, Yu M, Lakshmanan M, Pechtner V, van Brunt K. Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015;17:896-903.